TY - JOUR
T1 - Current state of hypnotic use disorders
T2 - Results of a survey using the Japanese version of Benzodiazepine Dependence Self-Report Questionnaire
AU - Yamamoto, Mai
AU - Inada, Ken
AU - Enomoto, Minori
AU - Habukawa, Mitsunari
AU - Hirose, Takahisa
AU - Inoue, Yuichi
AU - Ishigooka, Jun
AU - Kamei, Yuichi
AU - Kitajima, Tsuyoshi
AU - Miyamoto, Masayuki
AU - Shinno, Hideto
AU - Nishimura, Katsuji
AU - Ozone, Motohiro
AU - Takeshima, Masahiro
AU - Suzuki, Mayumi
AU - Yamashita, Hidehisa
AU - Mishima, Kazuo
N1 - Funding Information:
Author TH received personal fees from Sanofi, Eli Lilly, Novo Nordisk Pharma, Boehringer Ingelheim, Daiichi‐Sankyo, Mitsubishi Tanabe, MSD, Takeda, Dainippon Sumitomo, Ono, Astra Zeneca, Kowa, Kissei, Takeda and he has received research/grant support from Boehringer Ingelheim, Astra Zeneca, Mitsubishi Tanabe, Novo Nordisk, Takeda, Ono, MSD, Daiichi Sankyo, Dainippon Sumitomo, Novartis, Taisho, Astellas; author KI received personal fees from Dainippon Sumitomo Pharma, Eisai, Eli Lilly Japan, Janssen pharmaceutical, Meiji Seika Pharmaceutical, Mochida, MSD, Novartis, Otsuka Pharmaceutical, Shionogi, Tanabe‐Mitsubishi Pharma, and Yoshitomi Yakuhin, and grants from MSD; author JI received personal fees from Takeda Pharmaceutical and Astellas Pharma; KN received personal fees from Meiji Seika Pharma, Mochida, Takeda, Yoshitomiyakuhin, Pfizer, Eli Lilly, MSD, Shionogi, Janssen, Eisai, Astellas, Otsuka, Daiichi Sankyo, Nipro, Kissei, Tsumura, Novartis, Mitsubishi Tanabe, and Chugai and he has received research/grant support from Mochida, Takeda, Otsuka, Novartis, Mitsubishi Tanabe, Dainippon Sumitomo, MSD, Eisai, Tsumura, Eli Lilly, GlaxoSmithKline, and Mebix; author MT received personal fees from Daiichi Sankyo Company.; author TK received personal fees from Eisai, Tanabe‐Mitsubishi, Otsuka, Takeda, Eli Lilly, MSD, Meiji, Yoshitomi, Dainippon‐Suimitomo, Fukuda, Shionogi, and Novo Nordisk., and received research grants from Eisai, Takeda, MSD; and author KM received personal fees from Eisai, MSD, Takeda Pharmaceutical, and Astellas Pharma, along with research grants from Eisai, Nobelpharma and Takeda Pharmaceutical, and received research support from the Japanese Ministry of Health, Labour and Welfare (H29‐Seishin‐Ippan‐001, 19GC1012).
PY - 2020
Y1 - 2020
N2 - Aims: Benzodiazepine receptor agonists (BZ-RAs) are frequently prescribed to treat insomnia; however, their long-term use is not recommended. To introduce an appropriate pharmaco-therapy, the current state and background factors of BZ-RAs' dependence must be elucidated. In this study, we developed a Japanese version of the Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ-J) and conducted a study of BZ-RAs' use disorder. Methods: The Bendep-SRQ-J was created with permission from the original developer. Subjects were inpatients and outpatients receiving BZ-RAs between 2012 and 2013. Clinical data collected were Bendep-SRQ-J scores, sleep disorders for which BZ-RAs were prescribed, physical comorbidities, psychotropic drugs, and lifestyle factors. Logistic analysis was performed to extract factors associated with severe symptoms. Results: Of the 707 patients prescribed BZ-RAs, 324 had voluntarily tapered or discontinued their drugs. Logistic analysis showed that the total number of drugs administered in the last 6 months correlated with both worsening of symptoms or conditions. This was more notable among younger patients, and the proportion of patients with severe symptoms or conditions increased with the increasing number of drugs. Conclusion: Using the Bendep-SRQ-J, we elucidated the current state of BZ-RA dependence. Nearly half of the patients were non-compliant. The proportion of patients with severe symptoms or disease conditions increased with the increase in the number of drugs administered. These findings highlight the need for clinicians to be aware of the likelihood of benzodiazepine dependence, especially in young patients and patients prescribed multiple hypnotics.
AB - Aims: Benzodiazepine receptor agonists (BZ-RAs) are frequently prescribed to treat insomnia; however, their long-term use is not recommended. To introduce an appropriate pharmaco-therapy, the current state and background factors of BZ-RAs' dependence must be elucidated. In this study, we developed a Japanese version of the Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ-J) and conducted a study of BZ-RAs' use disorder. Methods: The Bendep-SRQ-J was created with permission from the original developer. Subjects were inpatients and outpatients receiving BZ-RAs between 2012 and 2013. Clinical data collected were Bendep-SRQ-J scores, sleep disorders for which BZ-RAs were prescribed, physical comorbidities, psychotropic drugs, and lifestyle factors. Logistic analysis was performed to extract factors associated with severe symptoms. Results: Of the 707 patients prescribed BZ-RAs, 324 had voluntarily tapered or discontinued their drugs. Logistic analysis showed that the total number of drugs administered in the last 6 months correlated with both worsening of symptoms or conditions. This was more notable among younger patients, and the proportion of patients with severe symptoms or conditions increased with the increasing number of drugs. Conclusion: Using the Bendep-SRQ-J, we elucidated the current state of BZ-RA dependence. Nearly half of the patients were non-compliant. The proportion of patients with severe symptoms or disease conditions increased with the increase in the number of drugs administered. These findings highlight the need for clinicians to be aware of the likelihood of benzodiazepine dependence, especially in young patients and patients prescribed multiple hypnotics.
UR - http://www.scopus.com/inward/record.url?scp=85096960436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096960436&partnerID=8YFLogxK
U2 - 10.1002/npr2.12149
DO - 10.1002/npr2.12149
M3 - Article
AN - SCOPUS:85096960436
JO - Neuropsychopharmacology Reports
JF - Neuropsychopharmacology Reports
SN - 1340-2544
ER -